Shangya Technology Co (6130) Fair Value & Analysis

Healthcare · TW · Market cap 1.3B TWD

Below-average quality, and screening another 70% overvalued on our models.

What matters now

• The price sits above even our optimistic bull case (11.53 TWD). The favourable scenario is already priced in.
• Weak quality (39/100) and above fair value at the same time, the margin of safety is missing on both counts.
• The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
• A fairly wide model range (5.77 TWD to 11.53 TWD) leaves room in how you read the outcome.

Price vs Fair Value (5 years)

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 21, 2026.

How to read this chart

60‑month range 17.53 TWD – 53.64 TWD · fair‑value band 5.77 TWD – 11.53 TWD · the 25.35 TWD price screens above the 7.73 TWD fair value. Dashed = 300-day average. As of Jul 21, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Shangya Technology Co (6130) currently trades at 25.35 TWD, while our model-based Fair Value estimate is 7.73 TWD, implying the stock looks roughly 69.5% overvalued today. The Quality Score stands at 39/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).

Over the trailing twelve months, Shangya Technology Co generated revenue of 154M TWD at a net margin of -47.4%. Revenue declined 0.9% year over year. It earns a return on equity of -14.1%. The balance sheet holds a net cash position of 114M TWD. Fundamentals as of Jul 21, 2026

Our scenario range runs from 5.77 TWD (bear case) to 11.53 TWD (bull case); at 25.35 TWD, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 48% below its 52-week high and 22% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -25% fair-value upside, at -70%, 6130 screens richer than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Key figures & financial health

Quality Score breakdown

About the company

Shangya Technology Co., Ltd. engages in the generic drugs and solar power generation businesses in Taiwan and Asia. The company wholesales Chinese and Western medicines, medical equipment, and beauty and hair care products; and onrito, lixin fumitation, lufuxing film-coated, amperex film coating, leverb-coated, triton film-coated, special core stabilized, …

Full company description

Shangya Technology Co., Ltd. engages in the generic drugs and solar power generation businesses in Taiwan and Asia. The company wholesales Chinese and Western medicines, medical equipment, and beauty and hair care products; and onrito, lixin fumitation, lufuxing film-coated, amperex film coating, leverb-coated, triton film-coated, special core stabilized, tanlipo film-coated, inhibitory film-coated, yoyo flat mouth dissolved, and binlishu film-coated tablet, as well as pain relief capsules and yue shi tong injection. It is also involved in the research, development, production, and sale of wireless communication integrated circuits, satellite positioning system integrated circuits, and portable product ICs. The company was formerly known as Singbao International Co. Ltd and changed its name to Shangya Technology Co., Ltd. in July 2023. Shangya Technology Co., Ltd. was founded in 1994 and is based in Taipei, Taiwan.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Shangya Technology Co reported revenue of 155M TWD in FY2025 versus 104M TWD in FY2021, a compound +10.5%/yr. Reported net income was −76.3M TWD in FY2025.

6130 screens 70% overvalued. Compare with Eli Lilly and Company →

Peer Group

Drug Manufacturers - General · 76 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Valuation Multiples vs Drug Manufacturers - General median · lower = cheaper

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 0: the price sits above our fair-value range.

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Drug Manufacturers - General stocks, each showing price versus our Fair Value estimate (as of Jul 21, 2026).

Explore undervalued stocks

More undervalued Healthcare stocks →

Frequently asked questions

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.